WHI-P97Janus kinase (JAK)-3 inhibitor CAS# 211555-05-4 |
- LY2835219
Catalog No.:BCC1113
CAS No.:1231930-82-7
- Roscovitine (Seliciclib,CYC202)
Catalog No.:BCC1105
CAS No.:186692-46-6
- Nu 6027
Catalog No.:BCC1154
CAS No.:220036-08-8
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- AT7519 Hydrochloride
Catalog No.:BCC1376
CAS No.:902135-91-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 211555-05-4 | SDF | Download SDF |
| PubChem ID | 3796 | Appearance | Powder |
| Formula | C16H13Br2N3O3 | M.Wt | 455.11 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : 5.88 mg/mL (12.92 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 2,6-dibromo-4-[(6,7-dimethoxyquinazolin-4-yl)amino]phenol | ||
| SMILES | COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C(=C3)Br)O)Br)OC | ||
| Standard InChIKey | YVCXQRVVNQMZEI-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H13Br2N3O3/c1-23-13-5-9-12(6-14(13)24-2)19-7-20-16(9)21-8-3-10(17)15(22)11(18)4-8/h3-7,22H,1-2H3,(H,19,20,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | WHI-P97 is a rationally designed potent inhibitor of JAK-3.
IC50 value:
Target: JAK3
Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal. WHI-P97 was very well tolerated in mice, with no signs of toxicity at dose levels ranging from 5 microg/kg to 50 mg/kg, and LD(10) was not reached at a 50 mg/kg dose level when administered as a single i. p. or i.v. bolus dose. References: | |||||
WHI-P97 Dilution Calculator
WHI-P97 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1973 mL | 10.9864 mL | 21.9727 mL | 43.9454 mL | 54.9318 mL |
| 5 mM | 0.4395 mL | 2.1973 mL | 4.3945 mL | 8.7891 mL | 10.9864 mL |
| 10 mM | 0.2197 mL | 1.0986 mL | 2.1973 mL | 4.3945 mL | 5.4932 mL |
| 50 mM | 0.0439 mL | 0.2197 mL | 0.4395 mL | 0.8789 mL | 1.0986 mL |
| 100 mM | 0.022 mL | 0.1099 mL | 0.2197 mL | 0.4395 mL | 0.5493 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
WHI-P97 is a rationally designed potent inhibitor of Janus kinase (JAK)-3.
- WHI-P154
Catalog No.:BCC2202
CAS No.:211555-04-3
- Dalcetrapib (JTT-705, RO4607381)
Catalog No.:BCC2328
CAS No.:211513-37-0
- Dendrobine
Catalog No.:BCN5923
CAS No.:2115-91-5
- Astrocasine
Catalog No.:BCN2150
CAS No.:2114-92-3
- R18
Catalog No.:BCC2383
CAS No.:211364-78-2
- m-Chlorophenylbiguanide hydrochloride
Catalog No.:BCC6650
CAS No.:2113-05-5
- 9,17-Octadecadiene-12,14-diyne-1,11,16-triol
Catalog No.:BCN1497
CAS No.:211238-60-7
- Rubranol
Catalog No.:BCN4917
CAS No.:211126-61-3
- Sobetirome
Catalog No.:BCC1957
CAS No.:211110-63-3
- Marsformoxide B
Catalog No.:BCN6687
CAS No.:2111-46-8
- SB 265610
Catalog No.:BCC5936
CAS No.:211096-49-0
- Mahanimbine
Catalog No.:BCN3174
CAS No.:21104-28-9
- WHI-P180
Catalog No.:BCC3928
CAS No.:211555-08-7
- Nudicaucin B
Catalog No.:BCN7843
CAS No.:211557-36-7
- Picroside IV
Catalog No.:BCN6533
CAS No.:211567-04-3
- 2',4',5'-Trimethoxy-2'',2''-dimethylpyrano[5'',6'':6,7]isoflavone
Catalog No.:BCN1496
CAS No.:211799-56-3
- Nudicaucin A
Catalog No.:BCN7842
CAS No.:211815-97-3
- Flumorph
Catalog No.:BCC5467
CAS No.:211867-47-9
- Gliclazide
Catalog No.:BCC5002
CAS No.:21187-98-4
- BIBR 953 (Dabigatran, Pradaxa)
Catalog No.:BCC2139
CAS No.:211914-51-1
- BIBR-1048
Catalog No.:BCC3738
CAS No.:211915-06-9
- 1,3,7-Trihydroxy-2-methoxyxanthone
Catalog No.:BCN7549
CAS No.:211948-69-5
- Vatalanib (PTK787) 2HCl
Catalog No.:BCC1111
CAS No.:212141-51-0
- Vatalanib
Catalog No.:BCC2085
CAS No.:212141-54-3
Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).[Pubmed:11082424]
J Pharmacol Exp Ther. 2000 Dec;295(3):912-26.
4-(3',5'-Dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97) is a rationally designed potent inhibitor of Janus kinase (JAK)-3. Treatment of mast cells with WHI-P97 inhibited the translocation of 5-lipoxygenase (5-LO) from the nucleoplasm to the nuclear membrane and consequently 5-LO-dependent leukotriene (LT) synthesis after IgE receptor/FcepsilonRI crosslinking by >90% at low micromolar concentrations. WHI-P97 did not directly inhibit the enzymatic activity of 5-LO, but prevented its translocation to the nuclear membrane without affecting the requisite calcium signal. WHI-P97 was very well tolerated in mice, with no signs of toxicity at dose levels ranging from 5 microg/kg to 50 mg/kg, and LD(10) was not reached at a 50 mg/kg dose level when administered as a single i. p. or i.v. bolus dose. Therapeutic WHI-P97 concentrations, which inhibit mast cell leukotriene synthesis in vitro, could easily be achieved in vivo after the i.v. or i.p. administration of a single nontoxic 40 mg/kg bolus dose of WHI-P97. Notably, WHI-P97 showed promising biological activity in a mouse model of allergic asthma at nontoxic dose levels. Treatment of ovalbumin-sensitized mice with WHI-P97 prevented the development of airway hyper-responsiveness to methacholine in a dose-dependent fashion. Furthermore, WHI-P97 inhibited the eosinophil recruitment to the airway lumen after the ovalbumin challenge in a dose-dependent fashion. Further development of WHI-P97 may therefore provide the basis for new and effective treatment as well as prevention programs for allergic asthma in clinical settings.
